Hedgehog Signaling Promotes Sorafenib Resistance in Hepatocellular Carcinoma Patient-derived Organoids

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2020 Jan 30

PMID 31992334

Citations 44

Authors

Siqi Wang

Yang Wang

Xiaodong Xun

Changkun Zhang

Xiao Xiang

Qian Cheng

Shihua Hu

Zhao Li

Jiye Zhu

Affiliations

Soon will be listed here.

Abstract

Background: The mechanism underlying sorafenib resistance in hepatocellular carcinoma (HCC) remains unclear. Accumulating evidence suggests that tumor-initiating cells (TICs) are a pivotal driving force. Both CD44 and Hedgehog signaling play crucial roles in TIC properties in HCC. In this study, we explored the roles of CD44 and Hedgehog signaling in sorafenib resistance and evaluated the therapeutic effect of cotreatment with sorafenib and Hedgehog signaling inhibitors in HCC patient-derived organoid (PDO) models to improve treatment efficacy.

Methods: We collected HCC specimens to establish PDO models. Cell viability and malignant transformation properties were investigated after treatment with different TIC-related inhibitors alone or in combination with sorafenib to evaluate the therapeutic effect in PDOs and cell lines by in vitro and in vivo experiments. Expression levels of Hedgehog signaling proteins and CD44 were monitored to reveal potential relationships.

Results: We demonstrated that our HCC PDO models strongly maintained the histological features of the corresponding tumors and responded to drug treatment. Furthermore, CD44-positive HCC PDOs were obviously resistant to sorafenib, and sorafenib increased CD44 levels. A drug screen showed that compared with Notch, Hippo and Wnt signaling inhibitors, a Hedgehog signaling inhibitor (GANT61) potently suppressed HCC PDO cell viability. In addition, there was a highly synergistic effect in vitro and in vivo on the suppression of cell viability and malignant properties when sorafenib and GANT61 were added to CD44-positive HCC PDOs and cell lines, respectively. Furthermore, the upregulation of CD44 and Hedgehog signaling induced by sorafenib was reversed by GANT61.

Conclusions: GANT61 significantly suppressed Hedgehog signaling to reverse sorafenib resistance in CD44-positive HCC. The combination of sorafenib and Hedgehog signaling inhibitors might be effective in HCC patients with high CD44 levels as a personalized-medicine approach.

Citing Articles

FBXO32 ubiquitination of SUFU promotes progression and lenvatinib resistance in hepatocellular carcinoma via hedgehog signaling.

Wang S, Peng R, Chen C, Tu D, Cao J, Su B Med Oncol. 2025; 42(4):98.

PMID: 40067532 DOI: 10.1007/s12032-025-02644-1.

Cancer stem-like cells stay in a plastic state ready for tumor evolution.

Xu J, Zhang H, Nie Z, He W, Zhao Y, Huang Z Neoplasia. 2025; 61:101134.

PMID: 39919692 PMC: 11851212. DOI: 10.1016/j.neo.2025.101134.

Hepatocellular carcinoma: signaling pathways and therapeutic advances.

Zheng J, Wang S, Xia L, Sun Z, Chan K, Bernards R Signal Transduct Target Ther. 2025; 10(1):35.

PMID: 39915447 PMC: 11802921. DOI: 10.1038/s41392-024-02075-w.

State-of-the-Art Liver Cancer Organoids: Modeling Cancer Stem Cell Heterogeneity for Personalized Treatment.

Giron-Michel J, Padelli M, Oberlin E, Guenou H, Duclos-Vallee J BioDrugs. 2025; 39(2):237-260.

PMID: 39826071 PMC: 11906529. DOI: 10.1007/s40259-024-00702-0.

Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy.

Cherradi S, Roux S, Dupuy M, Tabone-Eglinger S, Tuaillon E, Ziol M Sci Rep. 2025; 15(1):1179.

PMID: 39774014 PMC: 11706984. DOI: 10.1038/s41598-024-84304-4.

References

Lytle N, Barber A, Reya T . Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer. 2018; 18(11):669-680. PMC: 8388042. DOI: 10.1038/s41568-018-0056-x. View

Sicklick J, Li Y, Jayaraman A, Kannangai R, Qi Y, Vivekanandan P . Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis. 2005; 27(4):748-57. DOI: 10.1093/carcin/bgi292. View

Kim H, Cho H, Hong S, Cheong J . Hepatitis B virus X protein stimulates the Hedgehog-Gli activation through protein stabilization and nuclear localization of Gli1 in liver cancer cells. Cancer Lett. 2011; 309(2):176-84. DOI: 10.1016/j.canlet.2011.05.033. View

Villanueva A . Hepatocellular Carcinoma. N Engl J Med. 2019; 380(15):1450-1462. DOI: 10.1056/NEJMra1713263. View

Kudo M, Finn R, Qin S, Han K, Ikeda K, Piscaglia F . Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391(10126):1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. View

Duman-Scheel M, Weng L, Xin S, Du W . Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. Nature. 2002; 417(6886):299-304. DOI: 10.1038/417299a. View

Rani B, Malfettone A, Dituri F, Soukupova J, Lupo L, Mancarella S . Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression. Cell Death Dis. 2018; 9(3):373. PMC: 5841307. DOI: 10.1038/s41419-018-0384-5. View

Huang S, He J, Zhang X, Bian Y, Yang L, Xie G . Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis. 2006; 27(7):1334-40. DOI: 10.1093/carcin/bgi378. View

Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F . A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell. 2017; 172(1-2):373-386.e10. DOI: 10.1016/j.cell.2017.11.010. View

10.

Chou T . Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440-6. DOI: 10.1158/0008-5472.CAN-09-1947. View

11.

Sharma S, Haber D, Settleman J . Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010; 10(4):241-53. DOI: 10.1038/nrc2820. View

12.

Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D . Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut. 2015; 66(3):530-540. PMC: 5600200. DOI: 10.1136/gutjnl-2015-309501. View

13.

Roerink S, Sasaki N, Lee-Six H, Young M, Alexandrov L, Behjati S . Intra-tumour diversification in colorectal cancer at the single-cell level. Nature. 2018; 556(7702):457-462. DOI: 10.1038/s41586-018-0024-3. View

14.

Tuveson D, Clevers H . Cancer modeling meets human organoid technology. Science. 2019; 364(6444):952-955. DOI: 10.1126/science.aaw6985. View

15.

Kong Y, Wang Y, Zhu Z, Deng Z, Chen J, Zhang D . Silencing of the MEKK2/MEKK3 Pathway Protects against Spinal Cord Injury via the Hedgehog Pathway and the JNK Pathway. Mol Ther Nucleic Acids. 2019; 17:578-589. PMC: 6682310. DOI: 10.1016/j.omtn.2019.05.014. View

16.

Hu S, Fu W, Li T, Yuan Q, Wang F, Lv G . Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency. Sci Transl Med. 2017; 9(380). DOI: 10.1126/scitranslmed.aag0339. View

17.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

18.

Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, Gopalan A . Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014; 159(1):176-187. PMC: 4237931. DOI: 10.1016/j.cell.2014.08.016. View

19.

Goetz E, Ghandi M, Treacy D, Wagle N, Garraway L . ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Cancer Res. 2014; 74(23):7079-89. PMC: 4300142. DOI: 10.1158/0008-5472.CAN-14-2073. View

20.

Vidal S, Rodriguez-Bravo V, Galsky M, Cordon-Cardo C, Domingo-Domenech J . Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene. 2013; 33(36):4451-63. DOI: 10.1038/onc.2013.411. View